Digoxin

Digoxin, sold as Lanoxin, is a cardiac glycoside, a medicine taken by mouth in the form read here. The US label read, for Lanoxin tablets, lists three uses: mild to moderate heart failure in adults; increasing the strength of the heart muscle contraction in pediatric patients with heart failure; and controlling the ventricular response rate (how fast the lower chambers beat) in adults with chronic atrial fibrillation. For adults with heart failure the label says it improves symptoms, as shown by better exercise capacity and fewer heart-failure hospitalizations and emergency care visits, while having no effect on mortality. Its pediatric use section says safety and effectiveness for heart failure in children have not been established in adequate and well-controlled studies.

Also called Lanoxin

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 3407; UNII 73K4184T59. RxClass lists the FDA established pharmacologic class Cardiac Glycoside; the record is filed under the class page Cardiac glycosides (digoxin) on that evidence. The label read is the Advanz Pharma (US) Corp. label for Lanoxin tablets, application NDA020405, effective 2024-12-05 in openFDA. The Lanoxin injection label (NDA009330) and generic labels were not read. The adult and pediatric statements sit in separate claims and contexts. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.

About this drug

Level
Substance
Mechanism
The label says all of digoxin's actions come from its effect on the sodium-potassium ATPase enzyme, which raises the calcium available inside heart muscle cells.

Claims and evidence

Context Adults with heart failure or chronic atrial fibrillation, as described in the US label of Lanoxin tablets

Recipient
Adult
Population
Adults with mild to moderate heart failure, and adult patients with chronic atrial fibrillation, as the indications section of the label states.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Adults, as the label states
Follow-up
Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
Included
  • Adults with mild to moderate heart failure
  • Adult patients with chronic atrial fibrillation
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Lanoxin (digoxin tablets, Advanz Pharma (US) Corp., application NDA020405; the version dated 2024-12-05 in openFDA) describes digoxin as a cardiac glycoside. It lists the treatment of mild to moderate heart failure in adults, and the control of the ventricular response rate in adult patients with chronic atrial fibrillation. For adults with heart failure the label says the medicine improves heart failure symptoms, as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality.

    Applies to Adult Adults with heart failure or chronic atrial fibrillation, as described in the US label of Lanoxin tablets

    Certainty method
    Not assessed
    Limitations
    This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the label's own statements about exercise capacity and hospitalization are repeated only as the label states them; no trial result is recorded for it in this atlas. The pediatric use is in a separate claim. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (4)
    1. Supports openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      Label passage quoted in the research quote table (LB-04).
      Retrieved
      Source effective date
      2024-12-05
      Source state
      Current
      Version fingerprint
      9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1.1 Heart Failure in Adults
      How it applies
      Label passage quoted in the research quote table (LB-05, LB-10, LB-08).
      Retrieved
      Source effective date
      2024-12-05
      Source state
      Current
      Version fingerprint
      9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1.3 Atrial Fibrillation in Adults
      How it applies
      Label passage quoted in the research quote table (LB-06).
      Retrieved
      Source effective date
      2024-12-05
      Source state
      Current
      Version fingerprint
      9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Background openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20241205.
      Retrieved
      Source effective date
      2024-12-05
      Source state
      Current
      Version fingerprint
      9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Context Children with heart failure, as described in the US label of Lanoxin tablets

Recipient
Child
Population
Pediatric patients with heart failure, as the indications and pediatric use sections of the label state. The passages read give no age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Pediatric patients, as the label states; no ages given in the passage read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Pediatric patients with heart failure
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Lanoxin (digoxin tablets, Advanz Pharma (US) Corp., application NDA020405; the version dated 2024-12-05 in openFDA) says the medicine increases myocardial contractility in pediatric patients with heart failure. Its pediatric use section says the safety and effectiveness of Lanoxin in the treatment of heart failure in children have not been established in adequate and well-controlled studies.

    Applies to Child Children with heart failure, as described in the US label of Lanoxin tablets

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says about pediatric patients with heart failure. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label passage read gives no ages. The adult indications are recorded in a separate claim. Of the label's pediatric use section, only the sentence on heart failure in children is recorded; its other statements, and the dosing and safety sections, are not. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Supports openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1.2 Heart Failure in Pediatric Patients
      How it applies
      Label passage quoted in the research quote table (LB-07).
      Retrieved
      Source effective date
      2024-12-05
      Source state
      Current
      Version fingerprint
      9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].pediatric_use[0], 8.4 Pediatric Use
      How it applies
      The label's pediatric use section says safety and effectiveness for heart failure in children have not been established in adequate and well-controlled studies (LB-11).
      Retrieved
      Source effective date
      2024-12-05
      Source state
      Current
      Version fingerprint
      9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Background openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20241205.
      Retrieved
      Source effective date
      2024-12-05
      Source state
      Current
      Version fingerprint
      9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Pregnancy, lactation and children

The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.

In newborns, infants and children 1

Claims whose context is a newborn, an infant or a child.

  • Description Evidence stage not applicable Certainty not assessed

    The US label of Lanoxin (digoxin tablets, Advanz Pharma (US) Corp., application NDA020405; the version dated 2024-12-05 in openFDA) says the medicine increases myocardial contractility in pediatric patients with heart failure. Its pediatric use section says the safety and effectiveness of Lanoxin in the treatment of heart failure in children have not been established in adequate and well-controlled studies.

    Applies to Child Children with heart failure, as described in the US label of Lanoxin tablets

    Population, setting and follow-up
    • Pediatric patients with heart failure, as the indications and pediatric use sections of the label state. The passages read give no age range.
    • Prescription medicine, as described in the US label
    • United States (label of the US Food and Drug Administration)
    • Pediatric patients, as the label states; no ages given in the passage read
    • Gestational age Not reported
    • Postnatal age Not reported
    Follow-up Not applicable (label statement)
    Certainty method
    Not assessed
    Limitations
    This claim records what the label says about pediatric patients with heart failure. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label passage read gives no ages. The adult indications are recorded in a separate claim. Of the label's pediatric use section, only the sentence on heart failure in children is recorded; its other statements, and the dosing and safety sections, are not. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Supports openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1.2 Heart Failure in Pediatric Patients
      How it applies
      Label passage quoted in the research quote table (LB-07).
      Retrieved
      Source effective date
      2024-12-05
      Source state
      Current
      Version fingerprint
      9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].pediatric_use[0], 8.4 Pediatric Use
      How it applies
      The label's pediatric use section says safety and effectiveness for heart failure in children have not been established in adequate and well-controlled studies (LB-11).
      Retrieved
      Source effective date
      2024-12-05
      Source state
      Current
      Version fingerprint
      9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Background openFDA drug label record for Lanoxin (digoxin tablets), Advanz Pharma (US) Corp. label: indications, mechanism, class

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id d91e3646-4c63-4512-ab22-db39c085c4dc (manufacturer Advanz Pharma (US) Corp., application NDA020405), returned on 2026-11-18. The label text is dated 2024-12-05 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20241205.
      Retrieved
      Source effective date
      2024-12-05
      Source state
      Current
      Version fingerprint
      9fee123e88685b3bc779cac22fdbdea9c710b43114cc0c96fe54aebd7680f0fd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Record details

Record id
cardio:digoxin
Content hash
2c77036e6fc89c1fee24f6afd40546c689ef7aad1873464f7ee79de11fe47834